Results 31 to 40 of about 11,921 (104)

Effects of soluble guanylyl cyclase stimulation on muscle oxygenation and exercise capacity in heart failure with mildly reduced ejection fraction

Experimental Physiology, Volume 111, Issue 2, Page 474-488, 1 February 2026.
Abstract Heart failure (HF) with a mildly reduced ejection fraction (HFmrEF; 40%–49%) is present in ≤25% of HF patients. Therapeutic treatment options for HFmrEF‐associated exercise intolerance are limited. Nitric oxide (NO)‐independent stimulation of soluble guanylyl cyclase to improve peripheral vasodilatation offers a novel approach to enhance ...
Ramona E. Weber, Kiana M. Schulze, Andrew G. Horn, Tyler E. McCoach, Zachary J. White, K. Sue Hageman, Stephanie E. Hall, Peter Sandner, Brad J. Behnke, Timothy I. Musch, David C. Poole   +10 more
wiley   +1 more source

Rethinking Strategies for a Pharmaceutical Approach to Pain Related to Connective Tissue–Related Raynaud Phenomenon in the United States

Arthritis Care &Research, Volume 78, Issue 1, Page 106-112, January 2026.
Objective There are no US Food and Drug Administration–approved therapies for Raynaud phenomenon (RP) in the United States. Clinical trials have been challenged by study design. Important advances in RP patient‐reported outcome measures and mechanistic quantification allow RP‐related pain characterization.
Tracy M. Frech, Charles G. Frech, W. David Merryman, Andrew Sternlicht, Justin Baba   +4 more
wiley   +1 more source

Stimulator of interferon genes (STING)‐activating nanomedicines: Translating innate immune modulation into effective therapy for triple‐negative breast cancer

Clinical and Translational Medicine, Volume 16, Issue 1, January 2026.
Graphical representation of STING‐activated nanomedicines is for effective treatment of triple‐negative breast cancer. Abstract Triple‐negative breast cancer (TNBC), marked by profound immunosuppressive complexity, poses a critical challenge in therapy due to the absence of hormone receptors in its phenotype, making it unavailable for conventional ...
Harshita Singhai, Taha Alqahtani, Humood Al Shmrany, Garima Gupta, Umesh Kumar Patil, Amirhossein Sahebkar, Prashant Kesharwani   +6 more
wiley   +1 more source

Human hypoxia models in aerospace medicine: Potential applications for human pharmacological research

British Journal of Clinical Pharmacology, Volume 92, Issue 1, Page 58-72, January 2026.
Aerospace medicine required controlled terrestrial models to investigate influences of altered atmosphere conditions, such as hypoxia, on human health and performance. These models could potentially be expanded to encompass disease conditions or treatment targets regulated through hypoxia or hypercapnia.
Titiaan E. Post, Cayla Denney, Adam Cohen, Jens Jordan, Ulrich Limper   +4 more
wiley   +1 more source

Anti-Inflammatory and Anti-apoptotic Effects of Phosphodiesterase Inhibitors Against Streptozocin-induced Diabetic Nephropathy. [PDF]

In Vivo
Mehanna OM, Elesawy BH, Elaskary A, Hassan MGM, Ahmed WMS, El Monsef ASA, Abbas MAM, Hammad AM, Elgazzar UB, Gabr NM, El-Sharnouby M, Sharahili AI, Khalifa MM.   +12 more
europepmc   +1 more source

Intercellular diffusion of cyclic nucleotides followed by gap junction closure restarts meiosis in mouse preovulatory follicles. [PDF]

Proc Natl Acad Sci U S A
Nakashima IF, Zhong H, Nikolaev VO, Owen CM, Yee SP, Jaffe LA, Egbert JR.   +6 more
europepmc   +1 more source

Family-Wide Dysregulation of Phosphodiesterases Alters cAMP/cGMP Microdomains in Thoracic Aortic Aneurysm. [PDF]

J Cardiovasc Dev Dis
Magouliotis DE, Sicouri S, Androutsopoulou V, Baudo M, Cabrucci F, Zotos PA, Xanthopoulos A, Ramlawi B.   +7 more
europepmc   +1 more source

PDE10A as a novel diagnostic and therapeutic target in cancer: insights and challenges. [PDF]

Front Oncol
Ghoflchi S, Nakhaei A, Abbasinezhad-Moud F, Jalili-Nik M, Cimino PJ.   +4 more
europepmc   +1 more source

Phosphodiesterases Regulate <i>C. elegans</i> Bitter Taste Avoidance. [PDF]

MicroPubl Biol
Sojka SE, Hammond FM, Ferkey DM.
europepmc   +1 more source

Cyclic Nucleotide Phosphodiesterase Families as Targets to Treat Pulmonary Arterial Hypertension: Beyond PDE5 Inhibitors? [PDF]

Cells
Wang L, Fischmeister R, Manoury B.
europepmc   +1 more source